NSE
Amrutanjan Health Care LimitedAMRUTANJAN
Amrutanjan Health Care Limited is an Indian pharmaceutical company focused on the manufacturing and distribution of healthcare products.
| Key products | Pharmaceuticals, Ayurvedic medicines |
|---|---|
| Geography | India (domestic market) |
| Competitors | Dr Reddy's Laboratories, Cadila Healthcare |
AI-generated overview — verify before relying on it.
Net institutional flow
−₹28.8 Cr
Institutional buyers
1 in / 2 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Re 1 Per Share
ex 2026-02-06
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹7.2 Cr | 157 | — | — | — | — |
| 2 | QUADFUTURE | +₹0.1 Cr | 148 | — | — | — | — |
| 3 | MOBIKWIK | +₹0.1 Cr | 83 | — | — | — | — |
| 4 | AMRUTANJANThis | — | — | — | — | — | — |
| 5 | MTNL | +₹0 Cr | 2 | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 8 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Strong presence in the Indian pharmaceutical market
- • Diversified product portfolio with a mix of Ayurvedic and modern medicines
- • Established distribution network across India
- • Research and development capabilities
Weaknesses
- • Dependence on a few key products
- • High competition from established players like Dr Reddy's Laboratories
- • Regulatory challenges in the Indian pharmaceutical industry
- • Limited presence in international markets
Opportunities
- • Growing demand for Ayurvedic medicines in India and abroad
- • Increasing focus on healthcare and wellness in India
- • Potential for expansion into new product categories such as vaccines
- • Partnership opportunities with global pharmaceutical companies
Threats
- • Compliance risks due to regulatory changes
- • Fluctuations in raw material prices and supply chain disruptions
- • Intense competition from generic drugs
- • Rising healthcare costs and changing consumer preferences
AI-generated from our data — verify before relying on it.
- 2026-06-15Filing Nageswaramma Private Trust has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SShareholding Disclosure
- 2026-06-15Filing Amulya Kamakshi Priya Arikirevula has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) oShareholding Disclosure
- 2026-06-15Filing Ramaa Prabhakar Arikirevula has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Shareholding Disclosure
- 2026-02-06ActionInterim Dividend - Re 1 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Source PDF → - 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Source PDF → - 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Source PDF →
No bulk/block deals for AMRUTANJAN in this window.
News & chatter on AMRUTANJAN
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.